Suppression of NF-κB signaling and P-glycoprotein function by Gambogic acid synergistically potentiates Adriamycin -induced apoptosis in lung cancer

Current Cancer Drug Targets

Volumn 14, Issue 1, 2014, Pages 91-103

  Wang, Li Hui ^a,b   Yang, Jing Yu ^a   Yang, Sheng Nan ^a   Li, Yi ^a   Ping, Guan Fang ^a   Hou, Yue ^a   Cui, Wei ^a   Wang, Zhen Zhong ^b   Xiao, Wei ^b   Wu, Chun Fu ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b JIANGSU KANION PHARMACEUTICAL CO   (China)

Author keywords

Adriamycin; Apoptosis; Gambogic acid; Lung cancer; NF B; P glycoprotein

Indexed keywords

DOXORUBICIN; GAMBOGIC ACID; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG POTENTIATION; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; LUNG CANCER; MALE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DOXORUBICIN; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NF-KAPPA B; P-GLYCOPROTEIN; SIGNAL TRANSDUCTION; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892501644     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009613666131113100634     Document Type: Article

References (50)

1. Cataldo, V. D.; Gibbons, D. L.; Perez-Soler, R.; Quintas-Cardama, A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med. 2011, 364, 947-955.
2. Molina, J. R.; Yang, P.; Cassivi, S. D.; Schild, S. E.; Adjei, A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008, 83, 584-594.
3. Sugimura, H.; Nichols, F. C.; Yang, P.; Allen, M. S.; Cassivi, S. D.; Deschamps, C.; Williams, B. A.; Pairolero, P. C. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann. Thorac. Surg. 2007, 83, 409-417; discussioin 417-408.
4. Veronesi, A.; Magri, M. D.; Tirelli, U.; Carbone, A.; Mazza, F.; Franceschi, S.; Talamini, R.; Ardizzoni, A.; Canobbio, L.; Rosso, R. et al. Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide. A randomized study. Am. J. Clin. Oncol. 1988, 11, 566-571.
5. Huang, H.; Chen, D.; Li, S.; Li, X.; Liu, N.; Lu, X.; Liu, S.; Zhao, K.; Zhao, C.; Guo, H.; Yang, C.; Zhou, P.; Dong, X.; Zhang, C.; Guanmei.; Dou, Q. P.; Liu, J. Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett. 2011, 301, 221-228.
6. Zhu, X.; Zhang, H.; Lin, Y.; Chen, P.; Min, J.; Wang, Z.; Xiao, W.; Chen, B. Mechanisms of gambogic acid-induced apoptosis in nonsmall cell lung cancer cells in relation to transferrin receptors. J. Chemother. 2009, 21, 666-672.
7. Pandey, M. K.; Sung, B.; Ahn, K. S.; Kunnumakkara, A. B.; Chaturvedi, M. M.; Aggarwal, B. B. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 2007, 110, 3517-3525.
8. Chen, J.; Gu, H. Y.; Lu, N.; Yang, Y.; Liu, W.; Qi, Q.; Rong, J. J.; Wang, X. T.; You, Q. D.; Guo, Q. L. Microtubule depolymerization and phosphorylation of c-Jun N-terminal kinase-1 and p38 were involved in gambogic acid induced cell cycle arrest and apoptosis in human breast carcinoma MCF-7 cells. Life Sci. 2008, 83, 103-109.
9. Yu, J.; Guo, Q. L.; You, Q. D.; Zhao, L.; Gu, H. Y.; Yang, Y.; Zhang, H. W.; Tan, Z.; Wang, X. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 2007, 28, 632-638.
10. Guo, Q. L.; You, Q. D.; Wu, Z. Q.; Yuan, S. T.; Zhao, L. General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacol. Sin. 2004, 25, 769-774.
11. Li, Q.; Cheng, H.; Zhu, G.; Yang, L.; Zhou, A. Gambogenic acid inhibits proliferation of A549 cells through apoptosis-inducing and cell cycle arresting. Biol. Pharm. Bull. 2010, 33, 415-420.
12. Wang, X.; Chen, W. Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis. Anticancer Agents Med. Chem. 2012, 12, 994-1000.
13. Lü, L.; Tang, D.; Wang, L.; Huang, L. Q.; Jiang, G. S. Gambogic acid inhibits TNF-α-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-δB signaling pathways. Acta Pharmacol. Sin. 2012, 33, 531-541.
14. Wu, Z. Q.; Guo, Q. L.; You, Q. D.; Zhao, L.; Gu, H. Y. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol. Pharm. Bull. 2004, 27, 1769-1774.
15. Zhang, L.; Yi, Y.; Chen, J.; Sun, Y.; Guo, Q.; Zheng, Z. Song, S. Gambogic acid inhibits Hsp90 and deregulates TNF-alpha/NFkappaB in HeLa cells. Biochem. Biophys. Res. Commun. 2010, 403, 282-287.
16. YJ, C. Phase IIa clinical trial of Gambogic acid. Peking Union Medical College Dissertation of Master's Degree. 2005.
17. Zou, Z.; Xie, L, Wei, J.; Yu, L.; Qian, X. Synergistic antiproliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines. BMC Complement Altern. Med. 2012, 12.
18. Wang, J.; Liu, W.; Zhao, Q.; Qi, Q.; Lu, N. Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology 2009, 256, 135-140.
19. Zou, Z. Y.; Wei, J.; Li, X. L.; Yu, L. X.; Wang, T. T. Enhancement of anticancer efficacy of chemotherapeutics by gambogic acid against gastric cancer cells. Cancer Biother. Radiopharm. 2012, 27, 299-306.
20. Kurata, T.; Okamoto, I.; Tamura, K.; Fukuoka, M. Amrubicin for non-small-cell lung cancer and small-cell lung cancer. Invest. New Drugs 2007, 25, 499-504.
21. Pronzato, P.; Vigani, A.; Tognoni, A.; Vaira, F.; Canessa, P. Anthracyclines in non-small cell lung cancer. Lung Cancer 2001, 34, S57-S59.
22. Cummings, J.; Smyth, J. F. Pharmacology of adriamycin: the message to the clinician. Eur. J. Cancer Clin. Oncol. 1988, 24, 579-582.
23. Van Valen, F.; Fulda, S.; Schafer, K. L.; Truckenbrod, B.; Hotfilder, M.; Poremba, C.; Debatin, K. M.; Winkelmann, W. Selective and nonselective toxicity of TRAIL/Apo2L combined with chemo-therapy in human bone tumour cells vs. normal human cells. Int. J. Cancer 2003, 107, 929-940.
24. Koukourakis, M. I.; Koukouraki, S.; Giatromanolaki, A.; Archimandritis, S. C.; Skarlatos, J.; Beroukas, K.; Bizakis, J. G.; Retalis, G.; Karkavitsas, N.; Helidonis, E. S. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J. Clin. Oncol. 1999, 17, 3512-3521.
25. Otterson, G. A.; Villalona-Calero, M. A.; Hicks, W.; Pan, X.; Ellerton, J. A.; Gettinger, S. N.; Murren, J. R. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin. Cancer Res. 2010, 16, 2466-2473.
26. Patlakas, G.; Bouros, D.; Tsantekidou-Pozova, S.; Koukourakis, MI. Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer. Anticancer Res. 2005, 25, 1427-1431.
27. Bao, L.; Haque, A.; Jackson, K.; Hazari, S.; Moroz, K.; Jetly, R. Dash, S. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am. J. Pathol. 2011, 178, 838-852.
28. Khodadadian, M.; Leroux, M. E.; Auzenne, E.; Ghosh, S. C.; Farquhar, D.; Evans, R.; Spohn, W.; Zou, Y.; Klostergaard, J. MRP-and BCL-2-mediated drug resistance in human SCLC: effects of apoptotic sphingolipids in vitro. Lung Cancer 2009, 66, 48-57.
29. Campling, B.; Baer, K.; Gerlach, J.; Lam, Y.; Cole, S.; Mirski, S. Topoisomerase II levels and drug response in small cell lung cancer. Int. J. Oncol. 1997, 10, 885-893.
30. Andriollo, M.; Favier, A.; Guiraud, P. Adriamycin activates NFkappaB in human lung carcinoma cells by IkappaBalpha degradation. Arch. Biochem. Biophys. 2003, 413, 75-82.
31. Das, K. C.; White, C. W. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J. Biol. Chem. 1997, 272, 14914-14920.
32. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22, 27-55.
33. Zheng, L.; Yang, W.; Zhang, C.; Ding, W. J.; Zhu, H.; Lin, N. M.; Wu, H. H.; He, Q. J.; Yang, B. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett. 2011, 309, 27-36.
34. Zhang, H.; Yang, J. Y.; Zhou, F.; Wang, L. H.; Zhang, W.; Sha, S.; Wu, C. F. Seed oil of brucea javanica induces apoptotic death of acute myeloid leukemia cells via both the death receptors and the mitochondrial-related pathways. Evid. Based Complement Alternat. Med. 2011, 2011, 965016.
35. Pesic M.; Markovic, J.; Jankovic, D.; Kanazir, S.; Markovic I. D. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J. Chemother. 2006, 18, 66-73.
36. Yang, Y.; Yang, L.; You, Q. D.; Nie, F. F.; Gu, H. Y.; Zhao, L.; Wang, X. T.; Guo, Q. L. Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett. 2007, 256, 259-266.
37. Singh, R. P.; Mallikarjuna, G. U.; Sharma, G.; Dhanalakshmi, S.; Tyagi, A. K.; Chan, D. C.; Agarwal, C.; Agarwal, R. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin. Cancer Res. 2004, 10, 8641-8647.
38. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
39. Karin, M.; Cao, Y.; Greten, F. R.; Li, Z. W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2, 301-310.
40. Wang, C. Y.; Cusack, J. C, Jr.; Liu, R.; Baldwin, A. S., Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 1999, 5, 412-417.
41. Wang, C. Y.; Mayo, M. W.; Baldwin, A. S.; Jr. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NFkappaB. Science 1996, 274, 784-787.
42. Li, X.; Liu, S.; Huang, H.; Liu, N.; Zhao, C.; Liao, S.; Yang, C.; Liu, Y.; Zhao, C.; Li, S.; Lu, X.; Liu, C.; Guan, L.; Zhao, K.; Shi, X.; Song, W.; Zhou, P.; Dong, X.; Guo, H.; Wen, G.; Zhang, C.; Jiang, L.; Ma, N.; Li, B.; Wang, S.; Tan, H.; Wang, X.; Dou, QP.; Liu, J. Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo. Cell Rep. 2013, 3, 211-222.
43. Binkhathlan, Z.; Lavasanifar, A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr. Cancer Drug Target. 2013, 13, 326-346.
44. Kasibhatla, S.; Jessen, K. A.; Maliartchouk, S.; Wang, J. Y.; English, N. M.; Drewe, J.; Qiu, L.; Archer, S. P.; Ponce, A. E.; Sirisoma, N.; Jiang, S.; Zhang, H. Z.; Gehlsen, K. R.; Cai, S. X.; Green, D. R.; Tseng, B. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc. Natl. Acad. Sci. U S A 2005, 102, 12095-12100.
45. Anabousi, S.; Bakowsky, U.; Schneider, M.; Huwer, H.; Lehr, C. M.; Ehrhardt, C. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur. J. Pharm. Sci. 2006, 29, 367-374.
46. Xu, X.; Sutak, R.; Richardson, D. R. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. Mol. Pharmacol. 2008, 73, 833-844.
47. Kotamraju, S.; Chitambar C. R.; Kalivendi, S. V.; Joseph, J.; Kalyanaraman B. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J. Biol. Chem. 2002, 277, 17179-17187.
48. Volkova, M.; Russell, R. 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr. Cardiol. Rev. 2011, 7, 214-220.
49. Qi, Q.; You, Q.; Gu, H.; Zhao, L.; Liu, W.; Lu, N.; Guo, Q. Studies on the toxicity of gambogic acid in rats. J. Ethnopharmacol. 2008, 117, 433-438.
50. Zhao, L.; Zheng, C.; Wu, Z.; Hu, R.; Zhou, C.; Guo, Q. General pharmacological properties, developmental toxicity, and analgesic activity of gambogic acid, a novel natural anticancer agent. Drug Chem. Toxicol. 2010, 33, 88-96.